LLY

1,015.94

-0.68%↓

JNJ

194.16

-0.04%↓

ABBV

232.14

-1.25%↓

UNH

326.22

-2.02%↓

AZN

88.54

+0.6%↑

LLY

1,015.94

-0.68%↓

JNJ

194.16

-0.04%↓

ABBV

232.14

-1.25%↓

UNH

326.22

-2.02%↓

AZN

88.54

+0.6%↑

LLY

1,015.94

-0.68%↓

JNJ

194.16

-0.04%↓

ABBV

232.14

-1.25%↓

UNH

326.22

-2.02%↓

AZN

88.54

+0.6%↑

LLY

1,015.94

-0.68%↓

JNJ

194.16

-0.04%↓

ABBV

232.14

-1.25%↓

UNH

326.22

-2.02%↓

AZN

88.54

+0.6%↑

LLY

1,015.94

-0.68%↓

JNJ

194.16

-0.04%↓

ABBV

232.14

-1.25%↓

UNH

326.22

-2.02%↓

AZN

88.54

+0.6%↑

Strona główna・Stock List・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Open

SectorHealthcare

22.78 0.53

Buy Sell

Overview

Share price change

24h

Current

Min

22.45

Max

23.24

Key metrics
By Trading Economics
Income	675K 53M
Sales	1.8M 148M
P/E Sector Avg	12.608 105.69
Profit margin	35.57
Employees	181
EBITDA	-3.1M 76M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+49.25% upside

Market Stats
By TradingEconomics
Market Cap	26M 2.6B
Previous open	22.25
Previous close	22.78

News Sentiment

By Acuity

26%

74%

77 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

N/A / 24.28 Support & Resistance

Catalyst Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 lis 2025, 21:34 UTC

Earnings

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13 lis 2025, 23:45 UTC

Market Talk

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13 lis 2025, 23:42 UTC

Acquisitions, Mergers, Takeovers

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13 lis 2025, 23:41 UTC

Market Talk

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13 lis 2025, 23:24 UTC

Earnings

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13 lis 2025, 23:24 UTC

Earnings

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13 lis 2025, 23:23 UTC

Earnings

JBS NV 3Q EPS 52c >JBS

13 lis 2025, 23:23 UTC

Earnings

JBS NV 3Q Sales $22.6B >JBS

13 lis 2025, 23:04 UTC

Market Talk

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13 lis 2025, 22:02 UTC

Earnings

Nu Holdings 3Q Net $783M >NU

13 lis 2025, 22:01 UTC

Earnings

Nu Holdings 3Q Rev $4.2B >NU

13 lis 2025, 21:51 UTC

Acquisitions, Mergers, Takeovers

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13 lis 2025, 21:50 UTC

Earnings

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13 lis 2025, 21:45 UTC

Acquisitions, Mergers, Takeovers

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13 lis 2025, 21:41 UTC

Acquisitions, Mergers, Takeovers

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13 lis 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13 lis 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13 lis 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13 lis 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13 lis 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13 lis 2025, 21:33 UTC

Market Talk

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13 lis 2025, 21:33 UTC

Earnings

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13 lis 2025, 21:31 UTC

Earnings

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13 lis 2025, 21:25 UTC

Earnings

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13 lis 2025, 21:25 UTC

Earnings

Figure Tech Solutions 3Q EPS 34c >FIGR

13 lis 2025, 21:23 UTC

Earnings

Intchains Group 3Q Rev $1.3M >ICG

13 lis 2025, 21:03 UTC

Earnings

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13 lis 2025, 21:02 UTC

Earnings

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13 lis 2025, 21:01 UTC

Earnings

Applied Materials 4Q Rev $6.8B >AMAT

13 lis 2025, 21:01 UTC

Earnings

Applied Materials 4Q Gross Margin 48.0% >AMAT

Peer Comparison

Price change

Catalyst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

49.25% upside

12 Months Forecast

Average 34 USD 49.25%

High 35 USD

Low 33 USD

Based on 5 Wall Street analysts offering 12 month price targets forCatalyst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Catalyst Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 24.28Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

77 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.